9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation

Radiation therapy serves as an essential local-regional treatment modality across the breast cancer care continuum. Whether administered as adjuvant therapy following breast-conserving surgery or mastectomy, or deployed selectively in high-risk regional nodal basins, therapeutic radiation eradicates microscopic residual disease to optimize local control and enhance long-term overall survival.

Radiobiology and Fractionation Principles

Therapeutic radiation exerts its antineoplastic action by depositing ionizing energy within target tissues, leading to water radiolysis and the formation of reactive hydroxyl free radicals. These free radicals induce direct and indirect damage to cellular DNA, generating single-strand and double-strand breaks (DSBs). While single-strand lesions are readily repaired by endogenous enzymatic pathways, unrepaired or misrepaired double-strand breaks precipitate chromosomal aberrations, cellular senescence, and lethal mitotic catastrophe when malignant cells attempt division.

The clinical delivery of radiation therapy relies on the classic "Four Rs" of radiobiology:

• Repair: Normal healthy tissues possess superior sublethal DNA damage repair mechanisms compared to transformed malignant cells. Fractionating radiation into small daily increments allows normal breast parenchymal, vascular, and dermal cells to repair sublethal injury between fractions.
• Reoxygenation: Hypoxic tumor cells are notoriously radioresistant because molecular oxygen is required to chemically "fix" free radical-induced DNA lesions. As oxygenated outer tumor cells die, previously hypoxic inner cells become revascularized and reoxygenated, restoring radiosensitivity for subsequent fractions.
• Redistribution: Cells display variable radiosensitivity throughout the cell cycle, exhibiting peak vulnerability during the G2 and M (mitotic) phases, while remaining relatively resistant during late S-phase. Fractionated exposure allows surviving cells to cycle out of resistant phases and redistribute into radiosensitive phases.
• Repopulation: Between radiation treatments, both normal and malignant stem cells proliferate. Prolonged or unplanned gaps in treatment must be strictly avoided, as accelerated repopulation of tumor clonogens can compromise local control.

---

Whole Breast Irradiation: Conventional vs. Hypofractionated Regimens

Following breast-conserving surgery (lumpectomy), adjuvant whole breast irradiation (WBI) reduces the 10-year risk of in-breast recurrence by approximately 50% to 65% and produces a documented reduction in 15-year breast cancer mortality.

Conventional Fractionation

Historically, standard whole breast irradiation delivered 45 to 50 Gy in 25 daily fractions of 1.8 to 2.0 Gy over 5 weeks, Monday through Friday. A sequential boost to the surgical tumor bed—delivering an additional 10 to 16 Gy in 5 to 8 fractions using electrons or mini-tangent photons—was routinely added for patients at elevated risk of local recurrence (e.g., age younger than 50, high-grade histology, close surgical margins, or extensive intraductal component).

Hypofractionated Whole Breast Irradiation (HF-WBI)

Landmark randomized clinical trials (including the UK START-A and START-B trials, alongside the Ontario Clinical Oncology Group trial) demonstrated that moderate hypofractionation is equally effective as conventional schedules. HF-WBI delivers 40.05 to 42.5 Gy in 15 to 16 daily fractions of 2.66 to 2.67 Gy over 3 weeks. Long-term 10- and 15-year follow-up data established that HF-WBI yields equivalent local recurrence rates, equivalent overall survival, and equivalent or superior cosmetic outcomes, with significantly reduced acute skin erythema, less patient fatigue, and lower overall treatment costs. Current clinical consensus guidelines designate moderate hypofractionation as the preferred standard of care for the vast majority of patients undergoing whole breast irradiation, regardless of age, tumor grade, chemotherapy receipt, or breast size.

Ultra-Hypofractionated Radiation (FAST-Forward Trial)

Advances in treatment delivery fostered the development of ultra-hypofractionated regimens. The landmark FAST-Forward trial randomized over 4,000 women with early-stage breast cancer to 40 Gy in 15 fractions over 3 weeks versus 26 Gy in 5 daily fractions over 1 single week (5.2 Gy per fraction). At 5-year follow-up, 26 Gy in 5 fractions demonstrated non-inferiority in local tumor control (recurrence rate under 1.5%) and comparable normal tissue cosmetic toxicity. Ultra-hypofractionation represents an increasingly adopted standard, dramatically condensing treatment duration for eligible patients.

---

Post-Mastectomy Radiation Therapy (PMRT) and Regional Nodal Irradiation

Post-mastectomy radiation therapy (PMRT) is indicated for patients whose clinicopathologic features place them at substantial risk for locoregional recurrence on the chest wall or within regional nodal basins.

Definitive Indications for PMRT

Definitive clinical indications for PMRT include:

• Primary tumors greater than 5 cm in diameter (T3) or locally advanced disease with direct invasion into the chest wall or dermis (T4, including inflammatory breast cancer).
• Positive surgical resection margins that cannot be surgically re-excised.
• Four or more pathologically positive axillary lymph nodes (pN2 or pN3 disease).

Intermediate-Risk Nodal Disease (1 to 3 Positive Nodes)

For patients with 1 to 3 positive axillary lymph nodes (pN1), landmark meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) demonstrated that PMRT reduces both locoregional recurrence and breast cancer mortality. Radiation oncologists and multidisciplinary teams weigh intermediate risk against individual tumor biology, recommending PMRT when high-risk features coexist, such as young patient age (under 40 to 45 years), lymphovascular invasion (LVI), histological grade 3 disease, triple-negative receptor status, or extranodal extension (ENE) greater than 2 mm.

Regional Nodal Irradiation (RNI) Target Volumes

When regional nodal irradiation is indicated, treatment volumes are systematically contoured to encompass:

1. Supraclavicular Lymph Node Basin: Targeted to sterilize apical lymph node drainage in patients with high-risk axillary nodal involvement.
2. Internal Mammary Lymph Node (IMN) Chain: Located along the internal thoracic vessels in the first through third intercostal spaces. Targeted particularly when medial or central breast tumors present with axillary nodal involvement or when internal mammary nodes are radiographically abnormal.
3. Level III (Infraclavicular/Apical) Axillary Nodes: Routinely irradiated when the supraclavicular field is treated.
4. Axillary Levels I and II: Selectively irradiated if a formal axillary lymph node dissection (ALND) was omitted in the presence of positive sentinel nodes or when gross residual nodal disease is suspected.

---

Accelerated Partial Breast Irradiation (APBI)

Accelerated partial breast irradiation (APBI) delivers a localized dose of radiation strictly to the lumpectomy cavity plus a 1 to 2 cm margin of surrounding parenchymal tissue, completing therapy in 1 to 2 weeks (or as a single intraoperative fraction). APBI is predicated on the biological observation that 85% to 90% of in-breast local recurrences occur within or immediately adjacent to the original surgical bed.

ASTRO Criteria: The 2016 "Suitable" Group and the 2024 Guideline

The American Society for Radiation Oncology (ASTRO) 2016 consensus statement defined patients considered "suitable" for APBI outside of clinical trials:

• Patient age 50 years or older.
• Estrogen receptor-positive (ER+) disease.
• Unicentric and unifocal invasive ductal carcinoma or favorable histological subtypes (e.g., mucinous, tubular, cribriform).
• Pathologic tumor size 2.0 cm or smaller (pT1).
• Negative surgical resection margins of at least 2 mm.
• Pathologically node-negative axilla (pN0) with no evidence of lymphovascular invasion (LVI) and no known BRCA1 or BRCA2 germline pathogenic mutations.

ASTRO's 2024 clinical practice guideline replaced the suitable and cautionary groups. It recommends partial breast irradiation over whole-breast irradiation for node-negative invasive cancer that is grade 1 or 2, ER-positive, and small (2 cm or less) in patients 40 or older, conditionally recommends it for higher-risk features such as grade 3, ER-negative, or larger tumors, and recommends against it for patients younger than 40, known BRCA1/2 carriers, or those with positive margins. Low- to intermediate-grade DCIS of 2 cm or less in patients 40 or older is also a strong indication. The guideline does not recommend intraoperative radiation (IORT) alone outside clinical trials or registries.

APBI Delivery Modalities

APBI can be administered via several technological platforms:

• Intracavitary Brachytherapy: A balloon catheter (e.g., Contura) or multi-lumen strut device (e.g., SAVI applicator) is surgically inserted into the lumpectomy cavity. A high-dose-rate (HDR) Iridium-192 source travels through internal channels, delivering 34 Gy in 10 twice-daily fractions over 5 consecutive days.
• Interstitial Multicatheter Brachytherapy: Multiple flexible catheters are threaded through the breast tissue surrounding the lumpectomy bed, providing conformal dose modulation.
• External Beam 3D-CRT or IMRT: Non-invasive external photon beams deliver targeted fractions (e.g., 30 Gy in 5 once-daily fractions or 34 Gy in 10 twice-daily fractions) directly to the contoured cavity.

---

Advanced Delivery Techniques and Cardiac Sparing

Modern radiation planning relies on sophisticated technological innovations designed to maximize dose homogeneity within target tissue while sparing adjacent critical organs at risk (OARs), notably the heart, coronary arteries, and lungs.

Intensity-Modulated Radiation Therapy (IMRT) and VMAT

Intensity-Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) utilize computer-controlled multi-leaf collimators that dynamically move during beam delivery. By modulating beam fluence, IMRT minimizes excessive dose "hot spots" (areas receiving greater than 107% of the prescribed dose), which are common in patients with large or pendulous breasts treated with standard 3D-conformal wedges. This dose homogeneity significantly reduces the incidence of acute moist desquamation and long-term subcutaneous fibrosis.

Deep Inspiration Breath Hold (DIBH)

For patients with left-sided breast cancer, tangential radiation fields necessarily pass in close anatomical proximity to the anterior cardiac silhouette and the left anterior descending (LAD) coronary artery. Deep Inspiration Breath Hold (DIBH) is a voluntary respiratory gating technique utilized during CT simulation and daily treatment delivery:

• The patient inhales deeply, expanding the lungs with air and expanding the thoracic volume.
• Hyperinflated lungs physically push the diaphragm downward and displace the cardiac silhouette posteriorly and inferiorly away from the anterior chest wall.
• Computerized surface tracking monitors verify chest wall position, triggering radiation beam delivery only while the breath hold is maintained within millimeter precision.
• DIBH reduces the mean heart dose (MHD) by up to 50% to 70%, preventing late radiation-induced coronary endothelial injury, microvascular rarefaction, and accelerated coronary atherosclerosis.

Prone Positioning

Prone breast radiation positions the patient face down on an elevated treatment couch with an aperture through which the affected breast hangs suspended by gravity. This physical displacement pulls breast parenchyma away from the thoracic wall, reducing radiation exposure to the underlying myocardium and pulmonary parenchyma while eliminating inframammary skin folds.

---

Radiation Modalities, Fractionation, Indications, and Clinical Considerations

---

Acute and Late Radiation Toxicities: Clinical Nursing Management

Certified breast care nurses play an indispensable role in patient assessment, toxicities grading, preventive education, and evidence-based symptom interventions throughout radiation therapy.

Acute Radiation Dermatitis

Radiation dermatitis is the most prevalent acute toxicity, manifesting within 2 to 4 weeks of therapy as radiation damages proliferating basal keratinocytes in the epidermis.

• Grade 1 (Faint Erythema / Dry Desquamation): Mild reddening of the skin and dry peeling accompanied by itching and tightness. Nursing management includes gentle cleansing with lukewarm water and mild unscented soaps (e.g., Dove), patting dry without friction, and applying non-scented, water-based hydrophilic emollients (e.g., Aquaphor, Biafine, calendula creams) 2 to 3 times daily.
• Grade 2 (Moderate to Brisk Erythema / Patchy Moist Desquamation): Brisk skin erythema with localized areas of weeping, denuded epidermis predominantly confined to skin folds (inframammary fold, axilla). Nursing management includes saline soaks, application of non-adherent hydrogel sheets or soft silicone foam dressings (such as Mepilex Lite), and temporary use of mild topical corticosteroids (e.g., hydrocortisone 1%) for acute pruritus.
• Grade 3 (Moist Desquamation Beyond Skin Folds): Moist desquamation in areas other than skin folds, or bleeding with minor trauma (CTCAE v5), with significant pain and secondary infection risk. Managed with specialized barrier dressings, silver sulfadiazine cream (when cleared by the radiation oncologist), wound culture if purulence appears, and oral analgesia.
• Grade 4 (Skin Necrosis / Ulceration): Full-thickness dermal ulceration and necrosis. Radiation is held immediately, and wound care specialists or surgical teams are engaged.

Essential Nursing Skincare Principles

• Topical Application Timing: Many departments ask patients not to apply thick layers of cream just before treatment, but dosimetry studies show that a thin layer adds negligible surface dose, and current evidence reviews do not support routinely prohibiting deodorant or requiring patients to remove moisturizer before each fraction. Follow the treating department's instructions. The MASCC radiation dermatitis guideline also supports a mild topical corticosteroid (such as mometasone) to reduce dermatitis severity.
• Mechanical and Thermal Protection: Patients must avoid tight-fitting bras, underwires, and synthetic fabrics (recommending soft, breathable cotton), avoid adhesive tape on irradiated skin, avoid heating pads or ice packs, and refrain from shaving the treated axilla with straight razors (electric razors only).

Systemic and Late Toxicities

• Radiation Fatigue: A cumulative systemic fatigue that peaks toward the conclusion of treatment and persists for several weeks. Daily moderate aerobic physical activity (such as 20 to 30 minutes of walking) has the strongest evidence base for mitigating fatigue.
• Radiation Pneumonitis: Occurs in 1% to 5% of patients receiving regional nodal irradiation, manifesting 1 to 6 months post-treatment with dry cough, dyspnea, pleuritic chest discomfort, and low-grade fever. Diagnosed via CT demonstrating ground-glass opacities conforming to radiation portals; treated with an oral corticosteroid taper (prednisone).
• Late Tissue Changes: Long-term effects include chronic breast edema, subcutaneous fibrosis, telangiectasia, impaired cosmetic symmetry, capsular contracture around implants, rib microfractures, and rare secondary malignancies (such as radiation-induced cutaneous angiosarcoma, typically arising 5 to 10 years post-exposure).